Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
331 9 |
Ultima descărcare din IBN: 2024-05-07 07:09 |
SM ISO690:2012 PELTEC, Angela, IVANOV, Victoria, MUNTEANU (IVANOV), Mihaela, PELTEC, Inesa, POPOVICI, Mihail. Monacolin K as a treatment of hyperlipidemia in patients with nonalcoholic fatty liver disease . In: Journal of Gastrointestinal and Liver Diseases, 2016, nr. S2(25), pp. 223-224. ISSN 1841-8724. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Journal of Gastrointestinal and Liver Diseases | |||||||
Numărul S2(25) / 2016 / ISSN 1841-8724 /ISSNe 1842-1121 | |||||||
|
|||||||
Pag. 223-224 | |||||||
|
|||||||
Descarcă PDF | |||||||
Rezumat | |||||||
Background: Monacolin K is a fermented product of rice and red yeast (RYR) (Monascus purpureus). It is a potent inhibitor of HMG-CoA reductase – a substance that significantly reduces serum cholesterol levels, also known as lovastatin. Aim: To investigate the hypolipidemic effect of Monacolin K in patients with hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD). Methods: A total of 56 patients (mean age: 47.8 ± 1.8 years, 52 % males) who had a total cholesterol level of > 5.2 mmol/L and NAFLD were included in the study and allocated to receive Monacolin K 10 mg for 6 weeks. In all patients alcohol intake was reported to be less than 20 ml/day. We used ultrasound score as a criterion for NAFLD diagnosis. The 10-year risk of cardiovascular events was calculated according to the SCORE chart before and after treatment. As a primary outcome measure, we compared the before-after difference in lipid levels for patients included in the study. Results: Low density lipoprotein (LDL) cholesterol decreased from 4.19± 0.22 to 3.47± 0.14 mmol/L (-17.2%) (p<0.001), and total cholesterol from 6.46 ± 0.27 to 5.05± 0.16 mmol/L (-21.4%) (p<0.001). The lipid lowering effect resulted in a reduction of cardiovascular risk as measured with the SCORE chart, which changed from 3.85% to 2.5% . Conclusions: The RYR formulation under study was effective in lowering cholesterol and LDL cholesterol in patients with NAFDL. RYR therapy is an attractive alternative in patients with restrictions regarding pharmacological lipid lowering (high transaminase levels induced by NAFLD). |
|||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-162686</cfResPublId> <cfResPublDate>2016-09-20</cfResPublDate> <cfVol>25</cfVol> <cfIssue>S2</cfIssue> <cfStartPage>223</cfStartPage> <cfISSN>1841-8724</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/162686</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Monacolin K as a treatment of hyperlipidemia in patients with nonalcoholic fatty liver disease </cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Background: Monacolin K is a fermented product of rice and red yeast (RYR) (Monascus purpureus). It is a potent inhibitor of HMG-CoA reductase – a substance that significantly reduces serum cholesterol levels, also known as lovastatin. Aim: To investigate the hypolipidemic effect of Monacolin K in patients with hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD). Methods: A total of 56 patients (mean age: 47.8 ± 1.8 years, 52 % males) who had a total cholesterol level of > 5.2 mmol/L and NAFLD were included in the study and allocated to receive Monacolin K 10 mg for 6 weeks. In all patients alcohol intake was reported to be less than 20 ml/day. We used ultrasound score as a criterion for NAFLD diagnosis. The 10-year risk of cardiovascular events was calculated according to the SCORE chart before and after treatment. As a primary outcome measure, we compared the before-after difference in lipid levels for patients included in the study. Results: Low density lipoprotein (LDL) cholesterol decreased from 4.19± 0.22 to 3.47± 0.14 mmol/L (-17.2%) (p<0.001), and total cholesterol from 6.46 ± 0.27 to 5.05± 0.16 mmol/L (-21.4%) (p<0.001). The lipid lowering effect resulted in a reduction of cardiovascular risk as measured with the SCORE chart, which changed from 3.85% to 2.5% . Conclusions: The RYR formulation under study was effective in lowering cholesterol and LDL cholesterol in patients with NAFDL. RYR therapy is an attractive alternative in patients with restrictions regarding pharmacological lipid lowering (high transaminase levels induced by NAFLD).</p></cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Introducere: Monocolina K este un produs fermentat de orez și drojdie roșie (RYR) (Monascus purpureus). Acesta este un inhibitor puternic al HMG-CoA reductazei - substanța, care în mod semnificativ reduce nivelul colesterolului seric, de asemenea numită lovastatina. Scop: Evaluare efectul hipolipemiant al Monocolinei K la pacienții cu hipercolesterolemie și boala ficatului gras nonalcoolic (NAFLD). Metode: Un total 56 de pacienți (vârsta medie: 47,8 ± 1,8 ani; 52% bărbați), care au avut un nivel de colesterol total > 5,2 mmol/l și NAFLD au fost incluse în studiu și au primit Monocolina K 10 mg timp de 6 săptămâni. La toți pacienți consumul de alcool a fost raportat ca fiind mai mic de 20 ml/zi. Am folosit scorul ultrasonografic drept criteriu pentru diagnosticul NAFLD. Riscul de apariție evenimentelor cardiovasculare în următorii 10 ani a fost calculat în conformitate cu diagrama SCORE, înainte și după tratament. Pentru pacienții incluși în studiu ca măsură rezultatului primar, am comparat diferența nivelului lipidelor înainte și după tratament. Rezultate: Nivelul lipoproteinelor cu densitate joasă (LDL) a fost redus cu de la 4,19 ± 0,22 la 3,47 ± 0,14 mmol/l (-17.2%) (p <0,001), colesterol total de 6,46 ± 0 , 27 la 5,05 ± 0,16 mmol/l (-21,4%) (p <0,001). Efect de scădere a vilelului lipidelor a dus la reducerea riscului cardiovascular, masurata cu diagrama SCORE, care s-a schimbat de la 3,85% la 2,5%. Concluzii: Formula RYR folosită în studiului a fost eficace în scăderea colesterolului și a colesterolului LDL la pacientii cu NAFDL. Terapia RYR este alternativa atractivă la pacienții care au restricții privind diminuare farmacologică a nivelului lipidelor (nivel ridicat de transaminaze induse de NAFLD).</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11473</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11735</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-49211</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-102034</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-152</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11473</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11473-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> <cfFamilyNames>Пелтек</cfFamilyNames> <cfFirstNames>Анжела</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11735</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11735-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> <cfFamilyNames>Ivanov</cfFamilyNames> <cfFirstNames>Victoria</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-49211</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-49211-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> <cfFamilyNames>Munteanu (Ivanov)</cfFamilyNames> <cfFirstNames>Mihaela</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-102034</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-102034-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> <cfFamilyNames>Peltec</cfFamilyNames> <cfFirstNames>Inesa</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-152</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-152-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2016-09-20T24:00:00</cfStartDate> <cfFamilyNames>Popovici</cfFamilyNames> <cfFirstNames>Mihail</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>